You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202331 - 202340 of 207728 results
  1. Nanocarrier with metal bridge for affinity based delivery of metal binding peptid

    SBC: PHARMAIN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Lysostaphin, a metalloendopeptidase that is bacteriolytic for Staphylococcus aureus, is a potential systemic therapy for treating multidrug-resistant S. aureus mediated infections. However, the short half life of this e nzyme in vivo has precluded its development thus far as a systemic therapy. Our company, PharmaIN proposes to apply a novel drug delivery nanot ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Long Acting Native GLP-1 formulations for Type 1 Diabetes

    SBC: PHARMAIN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. The recent finding that islet cells can be regenerated in diabetic animals by the peptide hormone Glucagon- like peptide 1 (GLP-1) has raised the exciting possibility ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  3. EGF/Gastrin for islet cell regeneration

    SBC: PHARMAIN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of pancreatic islet cells in combination with immunosuppressant to avoid immune rejection is restricted to a subgroup of diabetics and is limited by th ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Long-acting VIP formulations for the treatment of chronic inflammatory diseases

    SBC: PHARMAIN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that are only poorly controlled. Vasoactive intestinal peptide (VIP) is an immunomodulatory peptide that induces regulatory T-cells and anti-inflammatory cytokine responses and has shown effi ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases

    SBC: PHARMAIN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that respond poorly. Suppressing NF-kB induction as treatment of chronic inflammatory diseases with a primary Th1-type cytokine profile (like e.g. Rheumatoid Arthritis, Multiple sclerosis, Ty ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Nanocarrier formulated enzyme for the treatment of S. aureus infection

    SBC: PHARMAIN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyso, a metalloendopeptidase that is bacteriolytic for S. aureus, is a potential systemic therapy for treating methicillin-resistant S. aureus (MRSA) mediated infections including endocarditis, osteomyelitis, catheter related infections, and MRSA-mediated community acquired furunculosis and pneumonia. However, the short half-life of this enzyme in vivo has prec ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Vasoactive intestinal peptide for the treatment of psoriasis

    SBC: PHARMAIN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Psoriasis is a chronic inflammatory skin disease that to this date is only insufficiently controlled by currently available treatments which can also come with severe, and sometimes life threatening side effects. In this application, we propose to create a new class of biologics drug for the treatment of this debilitating disease. We are proposing to formulate ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. EGF/Gastrin for Islet Regeneration

    SBC: PHARMAIN CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of pancreatic islet -cells, in combination with immunosuppressant to avoid immune rejection, is restricted to a subgroup of diabetics and is limited b ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder

    SBC: PHARMAIN CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Female sexual arousal disorder (FSAD), one of the conditions commonly described as Female sexual dysfunction (FSD) is common among older women and can be a significant reason for decreased quality of life in the aging population. FSAD is defined as the persistent or recurring inability to attain or maintain sufficient sexual excitement, causing personal distres ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Subcutaneous Drug Development for Portal Hypertension Ascites

    SBC: PHARMAIN CORPORATION            Topic: 300

    DESCRIPTION provided by applicant The prevalence of all types of ascites irrespective of the cause is in with of these due to cirrhosis Ascites is treated with a salt restricted diet and pharmacologic therapy using diuretics However in to of patients with ascites the ascites becomes refractory to medical therapy Half of patients who develop refractory ascites due ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government